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Peripheral nerve injuries occur through three mechanisms, specifically, crush, compression or transection. Disruption of com-
munication between the peripheral and central nervous system follows and leads to motor and sensory deficits. Peripheral nerves 
in humans have a limited capacity to self-regenerate following injury, which makes nerve transfer the current gold-standard for 
treatment. Functional nerve regeneration is contingent on several factors ranging from span of injury and the age of the patient. 
Bioprinted nerve guidance conduits are an emerging candidate for treating peripheral nerve injuries. To optimize the performance 
of nerve guidance conduits, a firm understanding of neurobiology and the pathophysiology following injury is necessary. This 
article provides an overview of nerve regeneration and the desirable features when designing a nerve conduit from a neurosurgi-
cal perspective. Biomed Rev 2019; 30:1-13
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INTRODUCTION 
The peripheral nerve injury remains one of the most common 
injuries encountered in the trauma and clinical setting. It is 
estimated that 20 million Americans suffer from peripheral 
nerve injury due to chronic diseases such as multiple sclerosis 
or more commonly, diabetes mellitus, as well as trauma (4). 
Majority of peripheral nerve damage being at the upper limbs 
in the order of frequency: radial, ulna and median. Whereas 
in the lower limb, comes in the order of frequency: sciatic, 
peroneal and tibial/femoral (5). Approximately 150 billion 
USD are spent yearly going towards the care and treatment 
for	peripheral	nerve	damage	(3).	Besides	the	financial	burden,	
the majority of the population who were affected by peripheral 
nerve cases were ages between 18 to 35 years old (6). Typical 
acute symptoms of peripheral nerve damage include sensory 
or motor loss of limbs, while chronic symptoms include neu-
ropathic pain and psychiatric issues (3). As a consequence, 
peripheral	nerve	damage	can	significantly	reduce	the	quality	
of life in many young and/or previously functionally normal 
patients.   
Abbreviations 
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The primary goal of nerve regeneration is to regain baseline 
sensory and/or motor function to the target organ. However, 
such regeneration greatly depends on the nerve gap, neuroma 
and scar tissue formation (3). Given that small nerves grow at 
a rate of 1 mm/day, while large nerve grow at a rate of 5 mm/
day, the accepted time window for peripheral nerve regenera-
tion is 12-18 months with some patient taking as long as 26 
months (3). While this regeneration is happening, atrophy of 
the	denervated	muscle	fibers	develops	immediately	and	after	
4 months, 60-80% of the muscle mass has been lost (sarcope-
nia). This leads to decrease in end organ function even after 
nerve regeneration (7). However, this concept is subjected to 
debate. As Sulaiman et al. have demonstrated there are, in fact, 
a reduced number of motoneurons that regenerate their axon 
to	the	muscle	fiber	unit,	and	not	the	muscle	unable	to	accept	
the innervations (8). Also, that previous studies have failed to 
account	for	growth	of	daughter	axons	from	a	single	nerve	fiber,	
and that previous research did not directly estimate the number 
of injured neurons that regenerated into the distal nerve stump, 
those	that	reinnervate	the	muscle	fiber	(8).	Despite	the	need	
to reduce peripheral nerve regeneration time, currently there 
are no treatments to achieve that. Therefore, most research has 
been focusing on reducing this time frame. 
The gold standard currently for peripheral nerve repair is 
direct surgical nerve repair with epineural microsutures (3). 
Other surgical techniques include grouped fascicular repair, 
free functioning muscle transfer (FFMT) and interpositional 
autologous nerve grafts (9). In an autologous nerve graft, the 
idea is that it will undergo Wallerian degeneration which serves 
a mechanical guidance and create a supportive structure for 
ingrowing axons (3). However, surgical nerve repairs have 
proved	problematic,	given	that	a	nerve	must	be	sacrificed,	and	
it	is	predisposed	to	complications	such	as	neuroma	and	fibrosis	
(3). Nerve transfer, where a proximal peripheral healthy nerve 
is	sutured	onto	the	damaged	nerve	has	shown	clear	benefits	
with	decreased	 regeneration	 time	 (7).	However,	finding	 an	
expandable	nerve	near	the	target	tissue	with	large	enough	fib-
ers may be a challenge to a lot of patients (10). Finally, FFMT 
directly transfer a healthy muscle and its neuromuscular bundle 
to a new location for a new function (9). This procedure is 
complex and very invasive that is only as the last option for 
reconstruction.    
Current translational research focus much on enhancing ax-
onal regeneration (Fig. 1) through growth factor action and 3D 
printed nerve conduit. Growth factors such as neurotrophin-3 
(NT-3),	nerve	growth	factor	(NGF),	fibroblast	growth	factor	
(FGF), glial cell-derived neurotrophic factor (GDNF), glial 
growth factor (GGF), ciliary neurotrophic factor and leupep-
tin have all been implicated in peripheral nerve regeneration 
(11). Nerve growth factor is important in nerve survival and 
outgrowth of neurites (12). In fact, NGF seeded conduits have 
better functional outcome then autograft in rabbit facial nerves 
(12). There are FDA approved commercially available nerve 
conduits on the market, but they have been shown not being 
effective in extensive lesions or larger nerves gaps greater 
than 3cm (13). 3D printed nerve conduit allow design and 
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create custom 3D scaffolds for nerve regeneration. Using 
“bioink” which include both synthetic and neutral material 
such as polyaniline (PANI), allow the grafting of certain cells 
such as Schwann cells (SC) and neurotropic factors into the 
conduit itself to encourage regeneration. Furthermore, scaf-
fold or conduit fabrication incorporates nanostructural and 
microstructural design components for regenerating complex 
tissues	with	patient-specificity	(14).						
(17). Finally, in 1988, Mackinnon and Dellon described a 
new type of peripheral nerve injury named type VI, which 
is a combination of Type II to IV. This type of injury maybe 
the most common in penetrating trauma and fracture, thus 
more	 reflective	 of	 real-life	 peripheral	 nerve	 damage	 (18).	
Currently,	Sunderland’s	classification	an	only	be	diagnosed	
histologically (19).




nerve injury, in which he distinguished three different types 
of nerve injury: Neurapraxia, Axonotmesis, Neurotmesis (15). 
Neuropraxia is the least serious and describes conduction 
blocks which leads to temporary sensory or motor lost. This 
type of injury is most commonly found in athletes. Axonotme-
sis is the next level of damage where the axon is irreversibility 
locally damaged, most commonly due to crush, nerve stretch 
and percussion injury. Finally, neurotmesis means the myelin 
sheath, axon and surrounding stroma are all injured, and no 
regeneration will occur unless there is surgical intervention. 
Such damage is most commonly associated with serious sharp 
or traction injuries (16).
In 1951, Sunderland (Fig. 2) expanded the peripheral nerve 
injury	classification	to	five	grades	which	provide	better	overall	
prognosis predictions (Table 1). Sunderland’s grade I and II 
can recover completely, while grade III recovers partially, and 
grade IV and V require surgical intervention (3). Compared 
to	the	Seddon’s	classification,	grade	I	corresponds	with	neu-
ropraxia, II to axonotmesis and III, IV and V to neurotmesis 
Figure 2. Sunderland classification of peripheral nerve inju-
ry. Image courtesy Cleveland Clinic, 2006. Illustrator, David 
Schumick, BS, CMI (1).
PATHOPHYSIOLOGY INJURY AND REGENERATION
Peripheral nerves can be injured in many ways including 
inflammation,	demyelination	and	trauma.	In	the	internal	neu-
ronal network, there is constant anterograde and retrograde 
transport and communication. Once these communications 
have been interrupted or that the neuronal lipid layer is dam-
aged, unless rapidly repaired there will be rapid and irreversible 
programmed cell death. Axonal degeneration happens both at 
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the proximal and distal ends of the zone of trauma (22).   
In the distal end, Wallerian degeneration ensues in the next 
24-48 hour in which the Schwann cell plays a large part (23). 
Once the SC sense that the axonal nerves are no longer con-
nected, it will transition from a mature, myelinating type or 
non-myelinated type (Remak cells) to a proliferative, repair 
SCs (Bungner SCs) (24) with the mRNA downregulation of 
myelin-associated proteins (e.g. P0, myelin-associated glyco-
protein) (11). The SC also reduce secretion of several proteins 
such as peripheral myelin protein 22 (PMP22), while increase 
the production of NGF and BDNF (9). The receptors of neu-
rotrophins (e.g. p75NTR, Trk A, TrkB, GDNF family receptor 
alpha-1 (GFRA-1), GDNF family receptor alpha-2 (GFRA-2) 
and cell adhesion molecules, e.g. neural cell adhesion mol-
ecule (NCAM), are upregulated (25). Collectively, these are 
also called regeneration-associated genes (RAGs). These im-
mature	SCs	will	be	influenced	by	the	mitogens	released	from	
the proximal damaged end and by cellular factors released 
by	other	cell	types	(ie.	fibroblasts)	as	well	as	blood-derived	
factors from breakdown of the blood brain barrier (BBB). The 
SC also release cytokines and recruit macrophages to the site 
of injury and participate in phagocytosis to clear up axonal 
and myelin debris within 3 weeks (11). After clearing the 
myelin debris, the SC will grow on the endoneurial tubes of 
the extracellular matrix creating the bands of Bungner, which 
serves as a guidance for nerve regeneration. It have been 
reported that pericytes, such as SCs, activate during wound 
healing,	inflammation	and	tissue	remodeling	(26).	These	ac-
tivated pericytes proliferate and follow the lead of angiogenic 
endothelial cells (26). Indeed, Cattin et al showed that hypoxia 
after peripheral nerve damage caused macrophages to stabilize 
Hypoxia-inducible	 factors	 1	 alpha	 (HIF-1α)	 and	 increased	
Vascular endothelial growth factor-A (VEGF-A) level (27). 
This induced vascularization, which becomes essential for 
SC to identify the direction for migration towards the distal 
stump (27). Interestingly, within the CNS SCs also travels 
along blood vessels to demyelinated lesions (28). EphrinB3 
within CNS myelin prevents SCs from adhering to the myelin, 
while enhancing them to bind to blood vessels extracellular 
matrix,	 especially	fibronectin,	 by	 upregulating	 	 integrinβ1	
expression (28).
In the proximal end, axon will undergo “dieback” degen-
eration, and daughter axons will begin to sprout and elongate 
from a growth cone (29) through the scars and into the distal 
end stumps. These are called the “regenerating units”. Since 
the proximal end is connected to the cell body, its nucleus 
within the cell body will undergo chromatolysis and move to 
an eccentric position and upregulate RAGs such as actin and 
GAP-43 (30). Based on direction signals from local tissue 
and denervated motor and sensory receptors, the growth cone 
sends	out	filopodia	to	sample	the	microenvironment	and	axons	
elongate (31). Guidance molecules including semaphorins, 
ephrins, netrins and slits are involved in this process (32). 
Neurotrophins such as NGF promote nerve regeneration by 
countering inhibitory regeneration signals such as the col-
lapsin-1 (33). Scar tissue and other debris impede the growth 
cone from advancing, thus proteases are produced and released 
to clear its path (34). 
Schwann cells and macrophages play a combinatory and 
reciprocal role in axonal regeneration. Schwann cells produce 
Table 1. Comparison of Sunderland and Seddon peripheral nerve injury classifications
Sunderland (20) Seddon (21) Pathology (11) Prognosis (16)
I Neuropraxia Demyelination Excellent 
II axonotmesis Demyelination with 
axonal lost
Good
III neurotmesis II + Involvement of 
endoneurium
Good-fair
IV neurotmesis III + Involvement of 
perineurium
Poor-nil





Mixed Combination of 
Sunderland’s II to IV
Varies
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NGF,	and	extracellular	matrix	components	such	as	fibronectin	
and laminin which allow the growth cone to make contact (35), 
while macrophages produce cytokines such as interleukin-1 
beta	(IL-1ẞ)	to	stimulate	NGF	production	by	SC	(36).	This	
creates a positive feedback loop. Once the growth cone is in 
contact with an endoneurial tube, it is most likely reaching 
the end organ or target and complete the regeneration (11).
If the growth cone does not come in contact with a receptor 
or an endoneurial tube or is impeded by the presence of several 
intraneural scarring, it will grow in a disorganized manner and 
produce a painful tissue mass of tangled axons and proliferat-
ing connective tissues known as a neuroma (37). The more 
severe the nerve injury, the more likely growth cones form 
neuromas due to increased scarring. This reduces the axonal 
regeneration	efficiency	(38).	Therefore,	nerve	damage	under	
grade III is considered as good prognosis when there is no 
endoneurial damage.
Besides the issue of scarring, prolonged axon regeneration 
can lead to reduction in nerve regeneration abilities. Sulaiman 
et al. have shown that after 6 months, RAGs are downregulated 
in a rodent model of chronic injury and delayed repair, leading 
to a reduced capability for nerve regeneration (39). However, 
recently, it has been reported that treatment with transform-
ing	growth	 factor-beta	 (TGF-β)	plus	 forskolin	 significantly	
increased expression of RAGs in chronic injured nerve and 
improved axonal regeneration (40, 41).
MICROSURGICAL REPAIR OF NERVE INJURIES
Advancements	 in	 illumination	 and	magnification	 have	 led	
to the emergence of microsurgical techniques comprising 
modern peripheral nerve repair. Contemporary nerve repair 
entails epineural adaptation of the proximal and distal nerve 
ends with minimal microsutures. This technique remains the 
gold standard for severe axonotmesis and neurotmesis injuries. 
Proximal and distal nerve stumps are correctly oriented prior to 
suturing	and	then	sealed	with	fibrin	glue.	This	method	of	repair	
is suitable for small nerve gaps below 2 cm in size. A nerve gap 
is the distance between the proximal and distal nerve stumps 
following injury and retraction due to elastic properties (42). 
Some studies have tested sutureless techniques e.g. laser weld-
ing which have yet to reach standard surgical practice (43, 44). 
End-to-end neurorrhaphy (EEN) has limited use since nerve 
regeneration requires tension-free coaptation to minimize 
intraneural scarring from postoperative movement. Repairs 
with tension endangers the vascular supply and increases the 
likelihood of scar formation (45). As a result, tension-free 
repair has become more crucial given the importance of exer-
cise in recovery after nerve injury (46-48). Well-vascularized 
regions represent another stipulation for neurorrhaphic repairs. 
An alternative technique is end-to-side neurorrhaphy (ESN), 
which may be useful in cases where the proximal nerve stump 
is not obtainable (49). In such circumstances, the distal stump 
is coapted to the side of the proximal stump. Collateral sprout-
ing is promoted in this technique and restores motor function. 
However, this technique has multiple drawbacks including the 
requirement of a donor nerve, minimal sensory recovery, and 
lower	efficacy	compared	to	EEN	(50).
NERVE TRANSFERS
Segmental nerve injuries necessitate nerve transfers and are 
considered the standard for bridging gaps in the peripheral 
nervous system (51). Nerve transfers coaptate a healthy nerve 
donor to a denervated nerve. Autografts for peripheral nerve 
repair are commonly harvested after the injured nerve is ex-
posed	from	superficial	sensory	nerves	such	as	sural,	saphenous,	
or the medial and lateral antebrachial cutaneous nerves. Three 
categories of autografts include trunk, cable, and vascularized 
nerve grafts (52). Differences in types of grafts produce better 
outcomes based on their components and the particularities of 
the injury. Endoscopic techniques have been introduced for 
nerve harvest. Grafts form a natural conduit that transfers the 
cellular (Schwann cells) and structural guide for regeneration. 
Advantages favoring autologous grafts include native tissue 
that promotes cell adhesion and migration with minimal im-
munogenicity (53). Autografts have been shown to be superior 
to epineural neurorrhaphy under tension (54, 55). However, 
several downsides exist for this treatment. Natural graft pro-
curement results in loss of function and risk of neuroma de-
velopment at the donor site, multiple grafts required for long 
nerve gaps, and size and fascicular incompatibility between the 
injured nerve and graft (56, 57). In contrast, allotransplanta-
tion of cadaveric nerve eliminates the loss of function at the 
donor site as a tradeoff for greater immunogenicity. Allografts 
require systemic immunosuppression and expose the patient 
to infection, decreased healing rate and other systemic effects 
(58). Decellularized and protein-free allografts exist to mini-
mize immune response. In clinical situations where extensive 
peripheral nerve injuries have been sustained allografts are 
utilized when donor material is in short supply. 
DESIGNING THE “IDEAL” NERVE CONDUITS
Current investments in research and development for periph-
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eral nerve regeneration are focused on nerve conduit design. 
Conduits promote axonal sprouting at the proximal end and 
guide regeneration towards the injured distal site via chemo-
tactic cues, stem cell seeding, and structural support. The 
ideal nerve conduit design will incorporate several properties 
including anisotropically arranged growth factors, enhanced 
stem cells, biocompatible and electroconductive materials, 
anatomical	specificity,	and	vascularity.
ROLE OF GROWTH FACTORS
Lately, incorporation of growth factors into the nerve conduit 
lumen	has	enhanced	the	efficacy	of	conduits	(59). Numerous 
polypeptides emanating from non-neuronal cells following 
injury promote the growth and guidance for nerve regenera-
tion. The most studied growth factors include NGF and BDNF 
(60), CNTF, insulin-like growth factor-1 (IGF-1), GDNF, 
TGF-ẞ1,	FGF-2,	GGF,	 and	neuregulins	 (61-63). Although 
these	 factors	have	been	 identified	 in	 the	microenvironment	
during nerve injury and repair, further research is required to 
ascertain mechanisms of action. Several problems exist with 
injecting neurotrophins into wound sites including their short 
half-life (instability) and the need for high-doses to elicit 
axonal sprouting (64). Neurotrophic instability means their 
effect is short-lived which diminishes their utility for long gap 
nerve injuries that take months to regenerate (64). High dos-
ages of neurotrophins can exaggerate axonal sprouting leading 
to entrapment and poor recovery outcomes (65). Axons also 
require topographic guidance cues to reach their distal targets 
that injections cannot communicate. This makes combining 
neurotrophic factors with conduit designs more attractive 
because it can mitigate these tendencies by controlling their 
release and longitudinal concentration.
Glial growth factor (GGF) is released following nerve injury 
and reportedly stimulates SC proliferation (66).  It promotes 
signaling exchange between neuronal and glial cells during 
peripheral nerve regeneration. Studies have incorporated GGF 
into conduits for defects spanning 2-4 cm resulting in elevated 
SC numbers, increasing axonal regeneration, and preventing 
muscle degeneration compared to control (67). Fibroblast 
growth factor (FGF) is another factor promoting cell growth 
and regeneration during nerve injury. Studies have incorpo-
rated FGF-2 into conduit biomaterial for treating 1 cm defects 
and reported greater regeneration compared to collagen-based 
matrices (68). 
Schwann cells produce NGF during Wallerian degeneration 
and promote nerve healing and regeneration (69, 70). When 
NGF is applied to poly [LA-co-(Glc-alt-Lys)] (PLGL) scaf-
folds it activates SC adhesion and prolongs their survival in 
vitro. Modifying NGF concentration or SC seeding in micro-
channels can both upregulate the overall NGF concentration 
in conduits (71, 72). Similar to NGF, CNTF is released from 
SC and nerve stump following injury and enhances sensory 
and motor neuron survival (72).
STEM CELL ENGINEERING
Stem cell transplantation has an important therapeutic role in 
stimulating peripheral nerve repair and regeneration. Neural 
stem cells (NSC) have the capacity to divide, proliferate, and 
differentiate into multiple lineages in vitro. Also, they can 
produce neurons, astrocytes, Schwann-like cells, and oli-
godencrocytes (73, 74). Several studies have produced NSCs 
from a variety of cells including human gingiva-derived mes-
enchymal stem cells (74), mesenchymal stem cells (75), and 
induced pluripotent stem cells (76). Differentiation of NSCs 
into Schwann-like cells have been used for peripheral nerve 
repair (77). Similar studies reported that NSCs promote axonal 
regeneration and myelination (78). Additionally, transplanta-
tion gingiva-derived mesenchymal stem cells can be induced 
into pluripotent cells and promote axonal regeneration (79). 
These	findings	may	be	attributed	to	several	cellular	features	
of NSCs including neurotrophic and neuroprotective factor 
production (BDNF, NGF, FGF, IGF-2, GDNF, etc.) (80-82). 
Further research is required to ascertain if NSCs generate suf-
ficient	levels	of	functional	cells	for	nerve	regeneration.	A	recent	
study has implemented CRISPR technology to selectively edit 
the genome of NSCs to produce both knock-out and knock-in 
cell lines (83). Selectively editing stem cells may upregulate 
genes for enhanced stem cell production of neurotrophic fac-
tors,	tubulins	for	axiogenesis,	or	anti-inflammatory	factors	for	
longer periods of time (84). Genetically	modified	NSCs	have	
been shown to accelerate proliferation and differentiation while 
maintaining the release of neurotrophic factors (85). 
Adipose-derived stem cells (ADSC) have been utilized 
greatly in peripheral nerve regeneration. Several advantages 
to comprise of ease of harvesting, abundance in supply, non-
immunogenicity,	and	efficacy	for	nerve	regeneration	(86,	87).	
Similar to NSCs, ADSCs likely regenerate nerves via differ-
entiation towards Schwann cells and subsequent release of 
trophic and neuroprotective factors (88). It is well documented 
that ADSC-populated conduits outperform empty conduits 
in several different nerve injuries (88, 89). The downside 
to using ADSCs is the low risk for teratoma formation after 
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differentiation into mesenchymal lineage (90). Clinical use 
of these cells would necessitate the investigation of ADSC 
spontaneous differentiation. 
BIOMECHANICAL DESIGN
Much emphasis has been placed on optimal nerve guidance 
conduit (NGC) design for promoting nerve regeneration (Fig. 
3). This section will review the lineage of NGC design evo-
lution. Hollow cylindrical NGCs were developed to bridge 
nerve	gaps	and	confine	axonal	regeneration	in	a	given	direc-
tion. Developers have made adjustments to materials (natural 
or synthetic) through various methods including crosslink-
ing, braiding, electrospinning, injection molding, melt extru-
sion techniques, or combinatorial approaches (91-93). Ma-
terials and fabrication methods produce unique mechanical, 
chemical, and biological properties. An important example 
involves the generation of electroconductive scaffolds for 
nerve regeneration. Conductive NGCs can improve periph-
eral nerve regeneration by increasing the expression of neu-
rotrophic factors and other cellular responses (94). Several 
studies have demonstrated polypyrrole-based conduits (PPY) 
comparable to autografts in rat sciatic nerve repair (95). Hol-
low	NGCs	 have	 been	 found	 to	 decrease	myofibroblast	 in-
filtration,	 scar	 formation,	 and	 collateral	 axon	 development	
(96). The downside to hollow NGCs is their limited capacity 
for chemotaxis necessary for axonal regeneration towards the 
distal stump. This results in poor functional recovery when 
compared to current clinical standards (97). Performance of 
hollow NGCs worsen as the gap widens generating disorgan-
ized axon growth (98).  
certain	components	(fibroblasts)	and	allow	more	desirable	re-
generative elements (100). Matrix loaded NGCs have spawned 
from porous NGCs to regulate the microenvironment of NGC 
channels.	Bioprinted	conduits	can	lay	down	specified	concen-
trations of components i.e. polysaccharides, proteins, growth 
factors to provide cues for axonal directionality (101). Matrices 
or hydrogels accelerate axonal regeneration for longer spans of 
nerve injury than hollow NGCs or empty porous NGCs (91). 
Popular	hydrogel	polymers	include	hyaluronic	acid,	fibrin,	and	
chitosan for their ability to direct nerve regeneration (91). The 
advent of hydrogels has spurred the emergence of anisotropic 
scaffolds. Anisotropic conduits vary concentrations of hydro-
gel and cellular components along the length of the conduit to 
exaggerate the guiding effects of chemical cues. This design 
feature further enhances axonal alignment and directionality 
towards the intended target.
VASCULARIZATION
Major transitions during the evolutionary development of 
vertebrates required overcoming the selective pressure of oxy-
gen and nutritional supplies. Primitive vasculature developed 
to counteract the metabolic drive and subsequent decline in 
surface area available for oxygen exchange for the interior 
cells of emerging multicellular organisms (102, also see John 
Torday’s review in this volume of Biomedical Reviews). In 
the case of nerve regeneration, studies have reinforced the 
importance	of	sustained	blood	flow	in	nerve	regeneration.	In	
acute nerve injuries, hyperemic conditions rather than ischemic 
conditions is the prevailing event resulting in focal edema (103, 
104). Other studies have elucidated the critical role of local 
microvessels in nerve regeneration by sustaining axonal sur-
vival through VEGF signaling and guiding axonal outgrowths 
to their target (105). Attempts to reinnervate long-standing 
nerve injuries have reported unreceptive microenvironments 
for	axiogenesis	likely	due	to	chronic	declines	in	blood	flow	
(106). Understanding the developmental processes for vascu-
larization is crucial for producing nerve conduits that promote 
vascular regeneration. 
Vasculogenesis is the developmental formation of vascu-
lar networks from differentiated endothelial precursor cells 
(EPCs) or angioblasts. Similarly, angiogenesis denotes the 
process of capillary growth from preexisting vasculature 
through sprouting or intussusception mechanisms (107). 
Finally, arteriogenesis is a distinct process generating small 
arterioles	with	low	blood	flow	to	larger	arteries.	Cellular	con-
trols driving the sequence of vasculogenesis and adulthood 
Figure 3. Extrusion-based 3D printing for NGC. 
Reproduced from (2).
To improve axonal regeneration, porous NGCs were de-
veloped to support components for nerve regeneration such 
as growth factors, SC, blood vessels, and nutrients (99). The 
pores are large enough for migration of SC to proceed. Degree 
of porosity or microchannel size has been tested to exclude 
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angiogenesis	have	been	identified	in	the	past	decade	(108).	
Growth factors involved in vessel formation include NGF 
(see	60	and	references	therein),	TGF-ẞ,	vascular	endothelial	
growth factor (VEGF), placenta growth factor (PIGF), FGF, 
platelet-derived growth factor (PDGF), and angiopoietins 
(107). Comparable to axiogenesis, sprouting vessels require 
growth factors to sustain development and chemotactic factors 
to guide sprouts properly (109, 110).
Developing a conduit that promotes peripheral neurovas-
cular regeneration is a major design obstacle. Limited studies 
are available merging these cellular processes, but studies 
have reported superior regeneration when nearby vascular 
bundles are connected to nerve conduits (111). Although nerve 
regeneration in the conduit group was inferior to the autograft 
group, electrophysiological and histological examinations 
reveals	 comparable	findings	between	 the	groups	 in	 rat	 and	
canine models. Incorporating vasculature into conduit design 
sustained nerve regeneration for 3cm-long-gaps. Development 
of neurovascular conduits would provide the foundation for 
regenerating other tissue types (dermis and muscle) in medi-
cal conditions.
ACCELERATION OF AXONAL REGENERATION THROUGH 
CONDUITS – ROLE OF FUNCTIONAL ELECTRICAL 
STIMULATION
A growing trend for nerve regeneration is the implementation 
of electrical stimulation (ES). As previously mentioned, ES 
and electroconductive conduits are effective tools for enhanc-
ing reinnervation following nerve transection. ES was found 
to accelerate the rate of axonal outgrowth in multiple studies 
(94).	Furthermore,	the	majority	of	ES	benefits	can	be	derived	
from stimulation for 1 hour at 20Hz (112). Gene expression is 
altered during ES that upregulates growth factor production, 
tubulin transport, and axonal elongation (113). Experiments 
have also found that ES promotes nerve regeneration despite a 
delay in nerve repair following injury in both rats and humans 
(30, 114). Incorporating the effects of ES into electroconduc-
tive conduit design should extend our capacity for spanning 
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